DNA technology for the detection of common genetic variants that predispose to thrombophilia

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 8, 2000, Pages 683-700

  Pecheniuk, N M ^a   Walsh, T P ^a   Marsh, N A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

DNA technology; Factor V Leiden; Methylene tetrahydrofolate reductase; Minisequencing; Polymerase chain reaction; Prothrombin 20210; Restriction fragment length polymorphism; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

CONFORMATIONAL TRANSITION; DNA DETERMINATION; ELECTROPHORETIC MOBILITY; ENZYME IMMUNOASSAY; GEL ELECTROPHORESIS; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HAPLOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION MAPPING; REVIEW; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; THROMBOPHILIA;

DNA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT MUTATION; THROMBOPHILIA; VARIATION (GENETICS);

EID: 0034538033     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200012000-00001     Document Type: Review

References (169)

1. Epidemiology of pulmonary embolism and deep vein thrombosis
2. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
3. Resistance to activated protein C as a basis for venous thrombosis
4. Anticoagulant protein C pathway defective in majority of thrombophilic patients
5. Mutation in blood coagulation factor V associated with resistance to activated protein C
6. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
7. Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis
8. Deficiency of protein C in congenital thrombotic disease
9. Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with history of venous thrombosis and criteria for rational patient screening
10. Prevalence of protein C deficiency in the healthy population
11. Protein C deficiency: A database of mutation, 1995 update
12. Recurrent venous thromboembolism in patients with a partial deficiency of protein S
13. Inherited thrombotic disorders: An update
14. Inherited antithrombin III deficiency causing thrombophilia
15. The prevalence of hereditary antithrombin III deficiency in patients with a history of venous thromboembolism
16. Antithrombin III mutation database: First update
17. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia
18. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V
19. The mechanism of inactivation of human factor V and human factor Va by activated protein C
20. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506 factor V
21. R506Q
22. The mechanism of inactivation of human factor Va from normal and activated protein C-resistant individuals
23. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
24. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
25. World distribution of factor V Leiden
26. High frequency of factor V Leiden in a population of Israeli Arabs
27. Prevalence of factor V Leiden and methylenetetrahydrofolate reductase C677T mutations in Azerbaijan
28. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher is Sweden than in other countries
29. Prevalence of the FVQ506 mutation in the Hellenic population
30. World distribution of factor V Leiden
31. Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C
32. High prevalence of factor V R506Q mutation in German thrombophilic and normal population
33. Q506 and prothrombin 20210 A mutations in an apparently healthy Icelandic population and patients suffering from venous thrombosis
34. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
35. Prevalence of factor V Leiden in a Canadian blood donor population
36. Low frequency of FV R506G mutation in a Finnish venous thrombosis population. XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy
37. Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors
38. Premature ischaemic heart disease and the gene for coagulation factor V
39. High prevalence of a mutation in the factor V gene within the U.K. population: Relationship to activated protein C resistance and familial thrombosis
40. Age as a risk factor for myocardial infarction in Leiden mutation carriers
41. World distribution of factor V Leiden
42. Frequency of factor V Arg506 to Gln mutation (FV Leiden) and activated protein C resistance in blood donors in Argentina. A preliminary study. XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy
43. Frequency of factor V arg506 in Italians
44. Factor V Leiden (FVQ 506) is common in a Brazilian population
45. Risk of thrombosis in patients homozygous and heterozygous for factor V Leiden in the East Bohemian region. XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy
46. Detection of the factor V Leiden mutation in a nonselected black population
47. (Factor V Leiden mutation among patients with venous thrombosis in India. XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy
48. Absence of factor V Leiden in the Japanese
49. World distribution of factor V Leiden
50. World distribution of factor V Leiden mutation
51. Very low incidence of Arg506→Gln mutation in the factor V gene among the Amazonian Indians and the Brazilian black population
52. A single genetic origin for a common Caucasian risk factor for venous thrombosis
53. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder
54. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease
55. Prevalence of 20210A allele of the prothrombin gene in venous thromboembolism patients
56. 20210→A in the prothrombin gene is a strong risk factor for pulmonary embolism
57. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia
58. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
59. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease
60. The prothrombin 20210A allele and its association with myocardial infarction
61. Geographic distribution of the 20210 G to A prothrombin variant
62. The mutation at position 20210 in the 3′-untranslated region of the prothrombin gene is extremely rare in Taiwanese Chinese patients with venous thrombophilia
63. The prothrombin gene G20210A mutation is not found among Japanese patients with deep vein thrombosis and healthy individuals
64. Absence of the prothrombin gene variant in Koreans
65. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene
66. The mutation Ala677→Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis
67. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase
68. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease
69. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
70. Molecular genetic analysis in mild hyperhomocysteinaemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease
71. Analysis of the 677 C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups
72. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans
73. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma
74. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
75. The factor V gene A4070G mutation and the risk of venous thrombosis
76. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (Factor V Leiden)
77. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C
78. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V
79. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma
80. Characterization of two forms of human factor Va with different cofactor activities
81. 2: Properties in the procoagulant and anticoagulant pathways
82. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene
83. Modified test for activated protein C resistance
84. A modification of the APC resistance test and its application to the study of patients on coumarin therapy
85. Modified APC resistance assay for patients on oral anticoagulants
86. Factor V Leiden-dependent APC resistance: Improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma
87. A new variant of interaction between phospholipid antibodies and the protein C system
88. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant
89. The PCAT - A simple screening assay for assessing the functionality of the protein C anticoagulant pathway
90. A chromogenic assay for activated protein C resistance
91. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia
92. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamin and folate concentrations in healthy subjects
93. The plasma homocysteine/creatinine ratio can be used to study the implication of (C677T) MTHFR genetic variants in homocysteine homeostasis
94. Rapid detection of the G1691A mutation of coagulation factor V by PCR-mediated site-directed mutagenesis
95. Rapid two-stage PCR for detecting factor V G1691A mutation
96. 506 of factor V associated with APC resistance and venous thromboembolism: Improved detection by PCR-mediated site directed mutagenesis
97. 506-factor V
98. Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin)
99. The 1691 G→A mutation in the factor V gene: Relationship to activated protein C (APC) resistance and thrombosis in 65 patients
100. A rapid screening method for the factor V Arg 506→Gln mutation
101. Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms
102. Simple and rapid combined genetic diagnosis of mutation (1691 G→A) of the factor V gene and (20210 G→A) of the prothrombin gene
103. Multiplex PCR-mediated site-directed mutagenesis for one-step determination of factor V Leiden and G20210A transition of the prothrombin gene
104. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
105. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance
106. Simple and rapid detection of factor V Leiden by allele-specific PCR amplification
107. Phenotyping and genotyping of coagulation factor V Leiden
108. Development of an ARMS procedure for the factor V Leiden mutation
109. Multiplex ASA PCR for a simultaneous determination of factor V Leiden gene, G→A 20210 prothrombin gene and C→T MTHFR gene mutations
110. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR
111. An alternative method for identifying the factor V gene Leiden mutation
112. Semi-automated detection of the factor V mutation by allele specific amplification and capillary electrophoresis
113. Simultaneous determination of methylenetetrahydrofolate reductase C677T and factor V G1691A genotypes by mutagenically separated PCR and multiple-injection capillary electrophoresis
114. Double fluorescent-amplification refractory mutation detection (dF-ARMS) of the factor V Leiden and prothrombin mutations
115. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
116. The usefulness of single-strand DNA conformation polymorphism analysis to detect mutations in protein C deficiency
117. A whole blood, multiplex PCR detection method for factor V Leiden and the prothrombin G20210A variant
118. Genetic diagnosis of factor V Leiden using heteroduplex technology
119. Factor V Leiden (G1691A, the prothrombin 3′-untranslated region variant (G20210A) and thermolabile methylenetetrahydrofolate reductase (C677T): A single genetic test genotypes all three loci-determination of frequencies in the S. Wales population of the UK
120. A polymorphism of glycoprotein IIb/IIIa, multiplexed with two prothrombotic genetic markers
121. Diagnosis strategies in activated protein C resistance: Is genotyping still necessary?
122. Detection of the 20210 A/G variation in the prothrombin gene by denaturing gradient gel electrophoresis (DGGE)
123. Multiplex PCR for one-step determination of the G20210A variation and the factor V Leiden mutation by denaturing gradient gel electrophoresis (DGGE)
124. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese
125. DGGE is more sensitive for the detection of somatic point mutations than direct sequencing
126. Simple and reliable factor V genotyping by PNA-mediated PCR clamping
127. Chemiluminescent detection of factor V Leiden in a routine laboratory
128. Detection of factor V Leiden using ASO (allele specific oligonucleotide)
129. Automated, simultaneous detection of the factor V Leiden and prothrombin (G20210A) variants using multiplex PCR and a line probe assay
130. Automated detection of the factor V Leiden mutation using the LCx microparticle enzyme immunoassay
131. Mutation in the gene coding for coagulation factor V and resistance to activated protein C: Detection of the genetic mutation by oligonucleotide ligation assay using a semi-automated system
132. A fast and robust dual-label nonradioactive oligonucleotide ligation assay for detection of factor V Leiden
133. Single nucleotide primer extension to detect genetic diseases: Experimental application to hemophilia B (factor IX) and cystic fibrosis genes
134. Rapid and simultaneous detection of multiple mutations by pooled and multiplex single nucleotide primer extension: Application to the study of insulin-responsive glucose transporter and insulin receptor mutations in non-insulin-dependent diabetes
135. Screening for defined cystic fibrosis mutations by solid-phase minisequencing
136. Detection of specific alleles by using allele-specific primer extension followed by capture on solid support
137. N-ras gene mutations in acute myeloid leukemia: Accurate detection by solid-phase minisequencing
138. Multiplex, fluorescent, solid phase minisequencing for efficient screening of DNA sequence variation
139. Convenient and quantitative determination of the frequency of a mutant allele using solid-phase minisequencing: Application to aspartylglucosaminuria in Finland
140. Genetic bit analysis: A solid phase method for typing single nucleotide polymorphisms
141. Minisequencing: A specific tool for DNA analysis and diagnostics on oligonucleotide arrays
142. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population
143. Polymorphism analysis and gene detection by minisequencing on an array of gel-immobilized primers
144. Towards automatic detection of point mutations: Use of scintillating microplates in solid-phase minisequencing
145. Template-directed dye-terminator incorporation (TDI) assay: A homogeneous DNA diagnostic method based on fluorescence resonance energy transfer
146. Homogeneous genotyping assays for single nucleotide polymorphisms with fluorescence resonance energy transfer detection
147. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E
148. A colorimetric minisequencing assay for the mutation in codon 506 of the coagulation factor V gene
149. A novel ELISA-based primer extension assay for the detection of the factor V Leiden mutation
150. Multiple analysis of three common genetic alterations associated with thrombophilia
151. Allelic discrimination of Factor V Leiden using a 5′ nuclease assay
152. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization
153. Detection of specific polymerase chain reaction product by utilizing the 5′→3′ exonuclease activity of Thermus aquaticus DNA polymerase
154. Molecular beacons: Probes that fluoresce upon hybridization
155. Molecular beacons: A new approach for semiautomated mutation analysis
156. Multiplex detection of single-nucleotide variations using molecular beacons
157. Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR
158. Rapid detection of the factor V Leiden (1691G→A) and haemochromatosis (845G→A) mutation by fluorescence resonance energy transfer (FRET) and real time PCR
159. High speed prothrombin G→A 20210 and methylenetetrahydrofolate reductase C→T 677 mutation detection using real-time fluorescence PCR and melting curves
160. Use of the direct RNA amplification technique NASBA to detect factor V Leiden, a point mutation associated with APC resistance
161. Nucleic acid sequence-based amplification
162. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
163. Falsepositive activated protein C (APC) sensitivity ratio caused by freezing and by contamination of plasma with platelets
164. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency
165. Factor V antigen levels in APC resistance, in factor V deficiency and in combined APC resistance and factor V deficiency (pseudohomozygosis for APC resistance)
166. A UK national external quality assessment scheme (UK Neqas) for molecular genetic testing for the diagnosis of familial thrombophilia
167. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase
168. Mutation detection and singlemolecule counting using isothermal rolling-circle amplification
169. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis